OTV is a global digital health fund with offices in Tel Aviv, NYC and Shanghai. The OTV mission is to invest in brilliant entrepreneurs, who are looking to touch the lives of those worldwide who will benefit from their innovative products and services in the digital health arena.

Sierra Ventures is a Bay Area-based early-stage venture firm investing globally with a focus on Next Generation Enterprise and Emerging Technologies. With over three decades of experience and over $2 billion of assets under management, Sierra has created a vast network of successful entrepreneurs, Global 1000 CXOs, operational executives, and deep domain experts, providing a platform for entrepreneurs around the world. Sierra Ventures primarily invests in Seed and Series A rounds, with a preference to lead investment rounds and reserve capital for follow on rounds. Investment sectors include artificial intelligence/machine learning, big data, cloud, fintech, health tech, IoT/infrastructure, marketplaces, SaaS & enterprise apps, security, and emerging technologies such as 5G, devices, blockchain, robotics, and virtual reality / augmented reality. Sierra Ventures typically makes initial investments between $500,000 and $7 million on average and invests between $500,000 and $15 million over the life of an investment. The firm has invested in leading companies such as Intuit, Invensense, Greenplum, MakeMyTrip, OnLink, Teradata, StrataCom, Sourcefire, Treasure Data, and more. Sierra Ventures was founded in 1982 and is based in San Mateo, California.

Sierra Ventures

Correlation Ventures is a new breed of venture capital firm, leveraging world-class analytics to offer entrepreneurs and other venture capitalists a dramatically better option when they are seeking additional capital to complete a financing round.

Correlation Ventures

Endurance is a holding company that manages diversified entrepreneurial projects, building nine successful companies amongst the partners since 2009.   The company actively manages four businesses founded by the Partners: Funding Circle US, Vocate, Collective Medical Technologies, and Endurance Properties.

Endurance Companies

ARTIS Ventures is a financial services firm that finances early-to-late-stage venture investments. The team supports its portfolio companies through their entire life cycle, from initial venture investment to public offering and beyond.

Artis Ventures (AV)

HV will act as an instrument of strategic growth in broadening Hikma’s offerings; it will allow Hikma to tap into opportunities in the growing digital health space.HV will invest in companies where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.We will invest in companies at all stages of development, including start-ups, spinouts, and consortia investments.Our initial investment size is up to $5 million per round. HV will look at global opportunities but with a focus on the US and the Middle East & Africa (MEA). We seek to actively partner with the management teams of portfolio companies to realize the potential of their products and technologies.

Hikma Ventures

Health Velocity Capital is to be the preferred innovation partner of entrepreneurs and investors working toward the common goal of a high quality, customer-friendly, affordable and sustainable healthcare system.

Health Velocity Capital

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management and board experience, and capital efficiency in the program. Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

Novartis Venture Fund

415 Ventures operates as a venture capital firm. Our  first investment is a social media-networking site called ViewersRepublic.com, which uses user-generated contents, i.e. videos, photos, blogs, and music to introduce and connect one member to another.  ViewersRepublic.com also serves as an alternative to iTunes and Amazon as a place to sell music. What we have over the other guys is that we do not take commissions out of the revenue the artists/bands make selling through us. We charge a one-time fee for setting up the album, and $20 a month for selling through us. In addition, we take the a lot of the stress out of out trying to get their music heard for indies because we provide a radio function that they can automatically add their music to, which is available for free streaming by ALL visitors. We also provide this service to major labels worldwide.

415 Ventures

Quest Diagnostics is a multinational clinical laboratory at the forefront of providing the world with diagnostic testing, information and services to empower patients and doctors to make better healthcare decisions.

Quest Diagnostics

3KVC is a New York-based venture fund focused on early-stage investments. The company intends to invest in the software and financial services industries.

Third Kind Venture Capital

Vega Ventures, LLC is a leader and innovator in the next generation of Internet Marketing Concepts. By way of their Family of Domains, they provide their sites members with an effective and cost efficient direct marketing strategy to the sites visitors through a practical an informative experience. As an advertising patner they provide a value driven model that takes advantage of navigation and direct placement strategies.

Vega Ventures

Founded in 2014 by Owen Van Natta and Grace Stanat. 415 provides seed funding for and advises (primarily early stage) companies. 415 assists in the areas of strategy, funding, deals/partnerships, social, e- and m-commerce, operations, user acquisition/engagement, culture and growth.

Civilization Ventures invests in visionary founders that are leading the future of health tech and biology-driven innovation. We aim to be the first check and lead investor in highly disruptive companies across digital health, synthetic biology, diagnostics, 3D (bio) printing, and AI/ software-enabled health tech. Our team comprises serial entrepreneurs and industry thought leaders who work tirelessly to help each of our portfolio companies succeed.

Civilization Ventures

Adaptive Healthcare Fund provides financial and strategic support to healthcare entrepreneurs with a focus on opportunities driven by healthcare transformation. Combining both hedge fund and private equity models, They are the first Southern California-based fund focused on healthcare innovation and next generation healthcare.  Their founders are seasoned entrepreneurs and executives with a track record of leadership at the nexus of healthcare strategy and business challenges. Adaptive Healthcare grew out of the vision of Harry Nelson and Rob Fuller, the co-chairs of the investment committee, who combine over four decades of healthcare industry experience. For Nelson, the founder of a suite of healthcare service organizations that have become a healthcare innovation “clearing house” in Southern California, the Fund extends his vision of problem-solving, connecting innovators and capital, and leading healthcare and life sciences companies down towards strategic growth.

Adaptive Healthcare Fund

Lemonaid Health

Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.

Lemonaid Health is a telehealth provider which treats many acute and chronic conditions. It was conducting clinical trials for at-home rapid Covid-19 testing services as of April 2020. The consultation fee is USD 25 (less than the cost of most insurance copays), which covers only the doctor's charge. Some behavioral healthcare services, such as depression and anxiety treatments, charge a flat monthly fee that covers consultations and any medicines that are prescribed. Many consultations happen over the phone, but doctors will switch to video consultation if it's necessary.

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

23andMe unit Lemonaid Health offering GLP-1 medication Ozempic and Wegovy

23andMe

The acquisition of Lemonaid health will provide 23andMe entry to the telehealth industrty and is looking to make its personalized genetics approach part of patients’ primary care. The company is also looking to make use of its pharmacogenetics reports—which help determine which drugs are likely to work best for an individual—when prescribing drugs through Lemonaid doctors.

A platform that facilitates the transmission of patient data to different locations for further evaluation and interpretation by medical specialists. 


Lemonaid Health is a telehealth provider which treats many acute and chronic conditions. It was conducting clinical trials for at-home rapid Covid-19 testing services as of April 2020. The consultation fee is USD 25 (less than the cost of most insurance copays), which covers only the doctor's charge. Some behavioral healthcare services, such as depression and anxiety treatments, charge a flat monthly fee that covers consultations and any medicines that are prescribed. Many consultations happen over the phone, but doctors will switch to video consultation if it's necessary.In October 2021, D2C genetic testing company 23andMe entered into a definitive merger agreement to acquire Lemonaid Health for a purchase price of USD 400 million. The deal is expected to close by the end of 2021. Following the acquisition, 23andMe plans to offer genetic testing in a primary care setting by integrating Lemonaid Health’s telemedicine and prescription drug delivery services with 23andMe’s personalized genetics services. 23andMe also plans to educate Lemonaid’s physicians on using its genetic reports for patient care. Lemonaid's CEO Paul Johnson will join 23andMe as the general manager of its consumer operations.In August 2024, the company planned to launch a GLP-1 weight loss telehealth membership by the end of the month. The service would enable members to be prescribed and receive brand-name or compounded semaglutide medications. The new offering would allow customers to access weight loss management services, fitting into the company's strategy of delivering services to improve individual health through preventive actions. The company's parent company, 23andMe, also planned to roll out a large-scale genetic research study to help identify the genetic mechanisms that may drive the efficacy and potential side effects of GLP-1 medications.

<div>
 
 Nice Healthcare is a US based telehealth company with a focus on primary care services to business-to-business (B2B) clients. Once the employer signs its employees with Nice (at a cost of USD 30 to USD 36 per employee per month), employees do not have to incur out of pocket expenses for Nice services and can schedule virtual or home visits within the time frames specified by the company. It connects patients with practitioners through a mobile app over video calls or text messages. Members can also request home visits which will be completed within a few hours, as claimed by the company. As of March 2022, Nice was operating in twelve states, and had over 400 small and medium enterprises (SMEs).
 
 
 In March 2022, the company raised USD 30 million in Series A financing led by DNA Capital which has been earmarked to expand its platform&rsquo;s reach among small and medium businesses. Additionally, the company is hiring three members for its management team to support the continuing growth of the organization.
 
 
 
</div>

Nice Healthcare

Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications.Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.

Amicomed

Winston is a men’s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients.The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.

Winston

<div>
 
 Dialogue partners with employers and health insurers to offer telehealth services to their employees and members. The users have 24/7 access to doctors, nurses, and other healthcare professionals via audio, video, and chat options for wide arrays of physical and mental health needs, artificial intelligence-enabled (AI-enabled) triage, referrals, and prescription renewals. 
 
 
 The company launched its trademarked Integrated Health Platform in January 2021 to consolidate its virtual care, wellness programs, mental healthcare services, and Employee Assistance Program (EAP) onto a single platform. The company claims to be the only integrated health and wellness B2B platform in Canada. 
 
 
 Key Customers and partnerships
 
 
 Dialogue had direct relationships with over 2,000 customers across Canada and Germany as of December 2020 and served around 50,000 organizations through these partnerships. In addition, the number of members with access to the virtual platform topped 1 million in January 2021. 
 
 
 Fundings and financials
 
 
 As of March 2021, Dialogue was planning to raise CAD 100 million (USD 80 million) from an initial public offering that will be listed on the Toronto Stock Exchange under the ticker symbol &ldquo;CARE.&rdquo; 
 
 
 In Q2 2023, net losses reduced significantly YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022. Top-line revenue met internal expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million), driven by &nbsp;an increase in new members (by 18.6% YoY), 
 an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac.
 
 Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
 <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
 acquired by financial services company Sun Life Financial
 </a>
 for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec. 
 
 
 
</div>

Dialogue

Grin offers telemedicine and remote monitoring services for orthodontic needs such as braces and teeth straightening. Patients can conduct self-scans (using a Grin device made available to patients in collaboration with 3M) which can be connected to their smartphones and share the feed with orthodontists to access dental solutions. The company plans to go to a subscription-based model after the pandemic. The app also encourages patients to have a 40-second check monthly and share the scan with a dentist in order to allow patients to regularly maintain their dental hygiene.Grin is the only Telehealth disruptor covered on the hub that provides virtual orthopaedic consultations.Funding and financialsIn April 2021, the New York-based teledental platform concluded a seed funding of USD 14 million, and the funds will be allocated to develop additional functionalities by building out its technology. The proceeds will also be used to scale up its team, expand its geographic footprint, and add doctors to the company’s orthodontic partner network.

Grin

Real-time collection of patients’ health-related data using any remote patient monitoring device combined with general telemedicine services to reduce readmission rates. 


A digital platform that offers specialty care services to address the specific needs of a patient or demographic, including consultations where patients are generally reluctant to meet practitioners face-to-face.

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app. 

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers. 

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 23andMe, the consumer genetic testing firm, intends to introduce a GLP-1 weight loss telehealth membership via its Lemonaid Health branch before the month ends. This service will grant members with prescriptions as well as distribution of brand-name or compounded semaglutide medicines. 
 This fresh offering will grant customers access to weight loss management services, aligning with the company's aim to provide services to enhance individual health through preventive measures. Additionally, 23andMe is charting out the course to conduct a large-scale genetic research study to identify the genetic mechanisms responsible for the efficiency and potential side effects of GLP-1 medicines.
 CEO Anne Wojcicki has stated that the company is of the belief that this new inclusion will generate longitudinal value that will aid members in staying focused on improving their health. The goal of 23andMe is to utilise its exclusive research model and vast customer base to expedite the study by reaching out to millions of customers who have given their consent to partake in research.
</div> Analyst QuickTake : 
 23andMe’s Lemonaid Health is the most recent telehealth provider beginning to offer and enable access to the GLP-1 weight loss medication. Recently, in May 2024, both <a href="https: 
//sp-edge.com/updates/29841"> Ro </a> and <a href="https: 
//sp-edge.com/updates/29605"> Hims &amp; Hers </a> began expanding access to the medication. However, while the medication is rapidly gaining popularity, physicians have noted that <a href="https: 
//www.fiercehealthcare.com/sponsored/physicians-say-glp-1s-are-imperfect-not-silver-bullet-solve-obesity-crisis#: 
~: 
text=Sponsored%20Health%20Tech-,Physicians%20say%20GLP%2D1s%20are%20imperfect%2C%20not%20%E2%80%9Csilver,bullet%E2%80%9D%20to%20solve%20obesity%20crisis&amp;text=As%20GLP%2D1s%20have%20risen,prescribe%20these%20weight%20loss%20medications."> it is not a "silver bullet" </a> that should be seen as the cure for the obesity crisis in the US. Due to GLP-1’s side effects, cost, and results, the treatment is claimed to be only sustainable for two to three years. As such, 23andMe’s planned genetic research study on the drug could shed more light on the treatment, either further validating its potential or helping support why more restraint should be exercised when prescribing the medication.

Lemonaid Health

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless